10月31日，第112届广交会医保展开幕。中国医保商会（以下称医保商会）最近公布的数据显示，2012年前3季度我国医药外贸进出口额698。6亿美元，同比增长11。4%。其中，出口353。5亿美元，增长7。8%；进口245。1亿美元，增长17。0%。新兴市场增长强劲。 

October 31,The 112th Canton fair on the medical insurance.China's health-care chamber of commerce(Hereinafter referred to as the medical insurance chamber of commerce)Recently published data display,2012 years ago our country medicine 3 quarter of foreign trade exports in 698.600 million dollars,Year-on-year growth of 11.4%.the,Export 353.500 million dollars,Growth and.8%;Imported 245.100 million dollars,Growth and.0%.Emerging market growth is strong. 

　　增幅意外下滑 

Growth falling accident 

　　与前些年20%以上的增速相比，今年医药外贸进出口增速明显下滑。“在当前严峻的经济环境和国内外监管环境趋严的条件下，我国医药外贸依然保持增长，并且高于全国外贸平均增速，说明整个行业已经付出了巨大努力。不过不可避免的是增速较往年有所放缓。”中国医保商会副秘书长谈圣采强调。 

And more than 20% of the growth in previous years compared,This medicine foreign trade import and export growth decline significantly."In the current grim economic environment at home and abroad and the regulatory environment strict conditions,Our country medicine foreign trade still maintained growth,And above the national average growth of foreign trade,Tell the whole industry has paid great effort.But inevitable is a growth slowed in previous years."China's health-care chamber of commerce deputy secretary general talk about saint mining stressed. 

　　出口增幅下滑相对较大。1～9月，中国医保产品出口数量增长6。10%，出口均价上升1。63%。据了解，年初医保商会已考虑到今年的市场风险，对出口增幅的预估下调至10%～15%，但市场的表现还是出乎意料，医保商会预计全年出口增长达到9%左右。根据以往的经验，医药出口每年年底一般会有一个小高峰，预计全年进出口增幅有可能达到12%左右。 

Export growth relatively large decline.1 ~ 9 months,China's health care products export quantity growth to 6.10%,Export average rise 1.63%.It is understood,Medical insurance at the beginning of the chamber of commerce has been considering this year's market risk,The estimate of export growth to cut to 10% ~ 15%,But the market performance or unexpected,Medical insurance chamber of commerce export growth throughout the year is expected to reach 9%.Based on past experience,Medical exports at the end of the year usually have a small peak,The import and export growth is expected to be 12%. 

　　谈圣采认为，今年的医药外贸形势是由多方面因素决定的。从市场方面看，处于世界医药主导地位的欧美市场经济萎缩，导致出口增长乏力；大宗原料药由于产能过剩引起的价格竞争对出口影响较大。与此同时，主要竞争对手印度、巴西等国家货币贬值也进一步降低了我国医药产品的国际竞争力。此外，经济发展不景气时，贸易保护和非技术性贸易壁垒等也会增加，对医药外贸的发展也会形成障碍。 

Talk about saint mining think,This year's foreign trade situation of medicine by various factors.See from market aspect,In the world medicine leading position of the European and American market economic contraction,Lead to export growth lack of power;Bulk API caused due to excess capacity for export price competition influences.meanwhile,The main rival India/Brazil and other countries currency devaluation also further reduce the our country medicine the international competition ability of the product.In addition,Economic development is bad,Trade protection and the technical barriers to trade and so on also will increase,The development of foreign trade in medicine will snag. 

　　不同产品遇到的问题也不尽相同。作为原料药出口大国，我国原料药出口数量虽然在不断增加，但利润和金额增幅明显放缓。制剂方面，由于缺乏拥有自主知识产权的原研品种，通过国际高端认证企业较少，进军欧美市场存在一定难度，主要还是在非主流市场销售，数量较少，价格相对低廉。不过，近年跨国企业在华投资设厂，产品返销欧美市场，对拉动制剂出口起到不小的作用。中药方面，受文化差异影响，在主流市场大多还是以膳食补充剂的身份出现，发展速度有限。但随着企业国际化步伐加快，欧美、东南亚等市场对中药认可度增加，未来发展潜力巨大。 

The problem of different products is endless also and same.As API exporter,Our country API export quantity while growing,But the amount of profit and growth slowed down obviously.Preparation aspects,Due to the lack of with independent intellectual property rights of the original research varieties,Through the international high-end authentication enterprise less,Into the European and American market has certain difficulty,The main or in the mainstream market sales,Number less,Relatively inexpensive.but,In recent years, the multinationals in China to invest,Buy-back the European and American market,In promoting the role of a big export preparation.In traditional Chinese medicine,By cultural differences influence,In most of the mainstream market or in the dietary supplements identity appear,Rate of development co., LTD.,.But as the enterprise internationalization to speed up the pace,Europe and the United States/Southeast Asia and other markets to increase business of traditional Chinese medicine (TCM),A huge potential for development in the future. 

　　据了解，今年生产成本上涨促使出口价格上涨，但出口价格上涨幅度低于成本上涨幅度，企业利润状况并无改观。“目前国内的人工成本和原材料成本处于上升阶段，影响医药企业的利润，进而影响企业再投入、再开拓的力度，持续发展能力受到影响。”谈圣采认为，过去金融危机时，医药刚性需求在外贸中有所体现，如今同样如此，相对其他产业来说，医药外贸依旧会持续稳定发展，但短期波动不可避免。 

It is understood,This year the production cost to rise in export prices,But export prices below cost rises,Enterprise profit and no change."The present labor costs and raw material costs in rise phase,Influence pharmaceutical enterprise profits,Further influence enterprise in again/To develop strength,Sustainable development capability affected."Talk about saint mining think,The past financial crisis,Medical rigid demand in foreign trade reflected somewhat in,Now the same,Relative to other industries,,Medical foreign trade still will continue to stable development,But short-term fluctuations inevitable. 

　　拓展新兴市场 

Expand emerging markets 

　　近期一系列退税、降低经营成本以及加大出口信用保险等外贸鼓励政策，给外贸企业带来支持。由于医药外贸占比较小，争取政策有一定难度。记者走访了本届广交会第三期参展商，不少代表称到会采购商明显减少，尤其是欧美采购商。 

The recent series of tax refund/To reduce operating costs and increase the export credit insurance, encourage foreign trade policy,To foreign trade enterprise to bring the support.Due to the medical trade accounts for smaller,For policy has the certain difficulty.The reporter interviewed the Canton fair in the third phase, the exhibitors,Many representative said to the purchaser significantly reduced,Especially in Europe and the United States buyers. 

　　对制剂出口企业而言，新兴市场采购商占比多或许并不是坏消息。中化宁波西成药部经理吴建强就坦言，国内制剂都是做新兴市场，“目前的总盘子很小，但市场很大，只是注册周期较长，需要时间加强营销网络布局。

The department of pharmaceutical preparation in terms of export enterprises,Emerging market buyers accounted for more than perhaps is not bad news.Sinochem ningbo west medicine manager WuJianJiang just said,Domestic preparation are doing emerging market,"The current total plate is very small,But a huge market,Only registered with a long cycle,Need time to strengthen the marketing network layout.